Here’s our Summer 2022 Roundup of top Maryland life sciences companies with more than 10 active job listings across a wide range of fields and experience levels.
BioFactura’s Dr. Jeffrey Hausfeld Offers Tips and Strategies for Physicians Looking To Turn Ideas Into Successful Businesses
Dr. Jeffrey Hausfeld, Chief Medical Officer and Chairman of the Board at Frederick, Maryland’s BioFactura and the Chairman and Co-Founder of the Society of Physician Entrepreneurs (SoPE), recently co-hosted an engaging webinar sponsored by DocWorking, a physician coaching organization.
American Gene Technologies recently named Dr. Jeff Boyle as its new Chief Science Officer. Boyle was previously President at Ellume USA where he led the build out of the company’s 180,000 square foot manufacturing facility in Frederick, Maryland that produces the first COVID-19 home self-test to receive an EUA from the FDA.
American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure clinical trial: it began withdrawing participants from their antiretroviral drugs earlier this month. This clinical protocol, technically known as analytic treatment interruption (ATI), may ultimately determine if this gene therapy treatment can cure HIV.
BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an antibody cocktail therapeutic for the treatment of smallpox.
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “Development of an Immunohistochemical Assay for Siglec-15” in Laboratory Investigation. The publication outlines data from a study, conducted in collaboration with researchers in the Department of Pathology at Yale School of Medicine, utilizing a newly developed antibody to Siglec-15 (S15) and an immunhistochemical (IHC) assay to investigate S15 expression in solid tumors.
WATCH NOW: Michael Richman on NextCure’s Cancer Treatment Innovations and the Rise of Biotech in Maryland
American Gene Technologies CEO Jeff Galvin sits down with Michael Richman, President & CEO of NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. With four clinical readouts and another IND application for a fourth program expected this year, NextCure is proving to be an emerging leader in immuno-oncology.
Jason received his bachelor’s degree in biology with a minor in chemistry from Frostburg State University. He has been in the biotech industry for 12 years, having spent most of that time in R&D, primarily immunology and in the manufacturing of biologics, making monoclonal antibodies and fusions proteins.
After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.
American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue the developments in monogenic disease and immuno-oncology.